EpiFluid, founded in Cincinnati, Ohio, is a medical organization dedicated to pioneering early detection methods for Alzheimer's disease through cfDNA (circulating free DNA) testing. Their core mission is to advance the understanding and diagnosis of neurodegenerative diseases by leveraging cutting-edge epigenomics and computational biology techniques. EpiFluid operates within the Simpson Querrey Institute for Epigenetics, the Department of Biochemistry and Molecular Genetics, and the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine.
Notable affiliated individuals include researchers and scientists from Northwestern University, who contribute to the lab's innovative approaches in decoding the human genome. EpiFluid has achieved significant milestones in developing high-throughput experimental methods in epigenomics, making impactful strides in early Alzheimer's detection. Their work not only promises to revolutionize diagnostic processes but also aims to improve patient outcomes through earlier intervention.
